VEGFA and melanoma: A phase I/II trial tested the safety and efficacy of imatinib in combination with bevacizumab (highly selective VEGF-A, the isoform that binds VEGF receptor (VEGFR) 1 and VEGFR2) in patients with advanced melanoma to prevent angiogenesis.